Drugs / Anti-HIV Immune Serum Globulin (Human)
Anti-HIV Immune Serum Globulin (Human)
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00000827 | ? → Apr 1998 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00002036 | — | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00000961 | ? → May 1991 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00000751 | ? → Aug 2007 | HIV infectious disease | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-HIV Immune Serum Globulin (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002036 ↗ |
| Known as | HIVIG | “To evaluate the effect of anti-HIV immune serum globulin (HIVIG) versus immune globulin (IVIG) administered during pregnancy and to the newborn, in combination with zidovudine...” NCT00000751 ↗2“To determine the safety and tolerance of hyperimmune anti-HIV intravenous immunoglobulin (HIVIG) and of zidovudine (AZT) in infants with established HIV infection” NCT00000961 ↗ “human anti-HIV immune serum globulin ( HIVIG ) at three dosage levels” NCT00000827 ↗ |
| Known as | human anti-HIV immune serum globulin | “human anti-HIV immune serum globulin ( HIVIG ) at three dosage levels” NCT00000827 ↗ |
| Known as | HVIG | “The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants” NCT00000961 ↗ |
| Modality | Protein / enzyme biologic | “Passive antibody therapy” NCT00000827 ↗ |
| Route | Intravenous | “hyperimmune anti-HIV intravenous immunoglobulin (HIVIG)” NCT00000961 ↗ |